US 6,362,194 C1 (5251st)
METHOD AND SIMULTANEOUSLY ENHANCING ANALGESIC POTENCY AND ATTENUATING DEPENDENCE LIABILITY CAUSED BY MORPHINE AND OTHER BIMODALLY-ACTING OPIOID AGONISTS
Stanley M. Crain, Leonia, N.J., and Ke-fei Shen, Flushing, N.Y., assignors to Albert Einstein College of Medicine of Yeshiva University, a division of Yeshiva University, Bronx, N.Y.
Reexamination Request No. 90/006,475, Dec. 2, 2002.
Reexamination Certificate for Patent 6,362,194, issued Mar. 26, 2002, Appl. No. 585,517, Jun. 1, 2000.
Continuation of application No. 09/094,977, filed on Jun. 16, 1998, now Pat. No. 6,096,756, which is a continuation of application No. 08/759,590, filed on Dec. 3, 1996, now Pat. No. 5,767,125, which is a continuation of application No. 08/552,296, filed on Nov. 3, 1995, now Pat. No. 5,580,876, which is a continuation-in-part of application No. 08/276,966, filed on Jul. 19, 1994, now Pat. No. 5,512,578, which is a continuation-in-part of application No. 08/097,460, filed on Jul. 27, 1993, now Pat. No. 5,472,943, which is a continuation-in-part of application No. 07/947,690, filed on Sep. 21, 1992, now abandoned.
This patent is subject to a terminal disclaimer.
Int. Cl. A01N 43/42 (2006.01)
U.S. Cl. 514—285
AS A RESULT OF REEXAMINATION, IT HAS BEEN DETERMINED THAT:
The patentability of claims 1-23 and 31 is confirmed.
Claims 24-30 are cancelled.
New claims 32-68 are added and determined to be patentable.
1. A method for selectively enhancing the analgesic potency of a bimodally-acting opioid agonist and simultaneously attenuating anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects associated with the administration of said bimodally-acting opioid agonist, comprising
administering to a subject an analgesic or sub-analgesic amount of a bimodally-acting opioid agonist selected from the group consisting of morphine, codeine, fentanyl analogs, buprenorphine, methadone, enkephalins, dynorphins, and endorphins, and an amount of an excitatory opioid receptor antagonist selected from the group consisting of naloxone and naltrexone effective to enhance the analgesic potency of said bimodally-acting opioid agonist and attenuate the anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects of said bimodally-acting opioid agonist.